Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850502 | 0.80 | MAPK1 (0.57) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL4128911 | 0.80 | MAPK1 (0.57) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL14782142 | 0.80 | MAPK1 (0.57) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL14782154 | 0.79 | MAPK1 (0.52) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL23031061 | 0.78 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL27999559 | 0.78 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL4038270 | 0.78 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL27282195 | 0.78 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL18547783 | 0.78 | MAPK1 (0.55) | MAPK1KDM4EL3MBTL1ALDH1A1ATM | |
| SCHEMBL1656723 | 0.78 | HDAC1 (0.55) | MAPK1KDM4EL3MBTL1ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 662 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768857-A | EZH2/HDAC double-target inhibitor and preparation method and medical application thereof | 中国药科大学 | 2023-09-19 | — | — | CN | claimed |
| CN-109232541-B | Prolyl hydroxylase and histone deacetylase dual inhibitor and preparation method and application thereof | 中国医学科学院放射医学研究所 | 2020-04-24 | — | — | CN | claimed |
| CN-109232541-A | Prolyl hydroxylase and histon deacetylase (HDAC) double inhibitor and its preparation method and application | 中国医学科学院放射医学研究所 | 2019-01-18 | — | — | CN | claimed |
| CN-122079878-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| CN-122079879-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079880-A | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12630509-B2 | Heterocyclic NMDA antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-19 | — | — | US | disclosed |
| CN-122036722-A | Hydroxamic acid compound of gamma-tetrahydrocarboline, and preparation method and application thereof | 浙江大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| EP-1981874-A1 | AMINOPHENYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | Janssen Pharmaceutica, N.V. (BE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008097428-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008046226-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-04-24 | — | — | WO | disclosed |
| WO-2007082878-A1 | AMINOPHENYL DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-26 | — | — | WO | disclosed |
| CN-1993353-A | Substituted indolyl alkylamino derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA NV (BE) | 2007-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630509-B2 | Heterocyclic NMDA antagonists | GRIN1, GRIN3A, GRIN2B | MAPK1 555/4885KDM4E 575/4885L3MBTL1 3347/4885 |
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | MAPK1 3571/4885KDM4E 4577/4885L3MBTL1 2268/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | MAPK1 105/4885KDM4E 1889/4885L3MBTL1 4499/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | MAPK1 3373/4885KDM4E 2690/4885L3MBTL1 177/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | MAPK1 2480/4885KDM4E 3064/4885L3MBTL1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.